The new plain language summary of publication in Future Cardiology uses information from the Fabry Registry to understand the effects of agalsidase beta treatment in women with Fabry disease.
Read the full article here.
The original article on which this summary is based is called ‘Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis’ and was originally published in the journal ESC Heart Failure. The original article can be read here.